<DOC>
	<DOCNO>NCT01305512</DOCNO>
	<brief_summary>Evaluation pharmacokinetic profile SPARC1028</brief_summary>
	<brief_title>Pharmacokinetic , Safety Tolerability Study SPARC1028</brief_title>
	<detailed_description>This phase I study SPARC1028 recommend phase II dose SPARC1028 administer week 3 week , follow 1 week rest .</detailed_description>
	<criteria>Histologically cytologically confirm diagnosis solid tumor advance stage taxanebased therapy rational treatment option . Age ≥18 year ECOG Performance Status ≤ 1 . Estimated life expectancy least 12weeks ; Any malignancy within past 5years , except nonmelanoma skin cancer , cervical intraepithelial neoplasia , situ cervical cancer Known hypersensitivity study drug Treatment anticancer agent within 28 day study entry Presence clinically evident active CNS metastasis , include leptomeningeal involvement , require steroid radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Solid</keyword>
	<keyword>Tumor</keyword>
	<keyword>Taxane</keyword>
</DOC>